Can pramipexole be used off‑label to treat anhedonia in an adult who failed a selective serotonin reuptake inhibitor or serotonin‑norepinephrine reuptake inhibitor and has no contraindications such as active psychosis, uncontrolled hypertension, severe cardiac disease, or a history of impulse‑control disorder?

Pramipexole for Anhedonia: Off-Label Use in Treatment-Resistant Depression

Pramipexole can be considered as an off-label augmentation strategy for anhedonia in adults who have failed SSRI/SNRI treatment, but this recommendation comes with significant caveats regarding impulse-control disorders, careful dose titration, and the need for close monitoring.

Evidence Base and Efficacy

The evidence supporting pramipexole for anhedonia is emerging but limited to small studies:

• A 2022 open-label pilot study (n=12) demonstrated significant improvements in anhedonia symptoms measured by the Dimensional Anhedonia Rating Scale (DARS), Snaith Hamilton Pleasure Scale (SHAPS), and Montgomery Åsberg Depression Rating Scale (MADRS) over 10 weeks of treatment. 1 This study also showed increased reward-related activity in the ventral striatum on fMRI, suggesting target engagement in dopaminergic reward circuits. 1

• A retrospective cohort study (n=116) of treatment-resistant depression showed that 74.1% of patients responded and 66.4% achieved remission after 24 weeks of pramipexole augmentation at a median maximum dose of 1.05 mg/day. 2 This included both unipolar (68%) and bipolar (32%) depression patients. 2

• The mechanism of action is relevant to anhedonia specifically, as pramipexole is a D2/D3 dopamine agonist that targets reward circuitry dysfunction associated with anhedonic symptoms. 1

Dosing Strategy

Start at 0.375 mg/day divided into three doses and titrate gradually up to a maximum of 4.5 mg/day based on response and tolerability. 3

• The effective dose range in depression studies has been 0.72-1.08 mg/day (median), though some patients required higher doses. 2
• Slow titration is essential to minimize peripheral side effects like nausea, vomiting, and orthostatic hypotension. 3

Critical Safety Concerns and Monitoring

Impulse-Control Disorders (Most Important Risk)

Pramipexole carries substantial risk for pathological gambling, hypersexuality, compulsive shopping, and other negative impulsive behaviors—this is an absolute contraindication if the patient has any history of impulse-control disorder. 4, 5

• These behavioral complications can cause severe personal and social handicap. 3
• Patients must be explicitly informed about these risks before initiating treatment and actively screened at every visit. 3

Neuropsychiatric Adverse Effects

• Excessive daytime somnolence, hallucinations, and delusions can occur and may severely limit use. 3
• Elderly patients with cognitive impairment have significantly increased risk of hallucinations compared to younger patients. 5

Cardiovascular and Other Monitoring

• Monitor for orthostatic hypotension, particularly at treatment initiation and dose escalations. 5, 3
• Assess for excessive daytime somnolence and fall risk. 5
• Screen for treatment-emergent suicidality, especially in the first 1-2 weeks. 6

Bipolar Disorder Considerations

If the patient has bipolar disorder (even if currently depressed), pramipexole must be combined with a mood stabilizer (lithium or valproate) to prevent manic switching. 7

• In the retrospective cohort study, bipolar patients received concurrent mood stabilizers and/or second-generation antipsychotics. 2
• One patient (0.9%) experienced a hypomanic switch in that study. 2

Clinical Algorithm for Decision-Making

1. Confirm diagnosis: Major depressive disorder or bipolar depression with prominent anhedonia (SHAPS score indicating significant anhedonia). 8, 1

2. Verify treatment resistance: Failed at least 2 adequate trials of different antidepressant classes. 2

3. Screen for absolute contraindications:

   • History of impulse-control disorder (gambling, hypersexuality, compulsive behaviors)
   • Active psychosis
   • Uncontrolled hypertension
   • Severe cardiac disease
   • Cognitive impairment/dementia (particularly concerning given hallucination risk) 5

4. If bipolar depression: Ensure patient is on adequate mood stabilizer before adding pramipexole. 7, 2

5. Initiate treatment: Start 0.375 mg/day divided TID, titrate slowly based on response. 3

6. Monitor closely:

   • Weekly for first month: impulse-control symptoms, orthostatic vital signs, sedation, psychotic symptoms
   • Every 2-4 weeks thereafter: same parameters plus anhedonia/depression rating scales
   • Assess response at 8-10 weeks before determining treatment failure 1, 2

Common Pitfalls to Avoid

• Failing to screen for and monitor impulse-control disorders: This is the most serious adverse effect and can cause devastating consequences. 4, 5, 3
• Using pramipexole as monotherapy in bipolar depression: Always combine with mood stabilizer. 7
• Inadequate dose titration time: Peripheral side effects (nausea, orthostatic hypotension) are common early but often resolve with slow titration. 3
• Prescribing to patients with cognitive impairment: Risk of hallucinations is substantially elevated. 5
• Insufficient trial duration: Allow 8-10 weeks at therapeutic dose before declaring treatment failure. 1, 2

Limitations of Current Evidence

The evidence base consists primarily of small open-label studies and retrospective cohorts with very low certainty of evidence. 4 A randomized controlled trial is currently underway (NCT05355337) but results are not yet available. 8 The 2023 AASM guideline rates pramipexole evidence as "very low" quality due to imprecision and risk of bias in observational studies. 4

Given the limited evidence and significant safety concerns, pramipexole should be reserved for carefully selected patients with prominent anhedonia who have failed multiple conventional treatments and have no contraindications, particularly no history of impulse-control problems.